Immediate Impact

6 from Science/Nature 74 standout
Sub-graph 1 of 23

Citing Papers

New promises and challenges in the treatment of advanced non-small-cell lung cancer
2024 Standout
Theranostic Fluorescent Probes
2024 Standout
7 intermediate papers

Works of Shevan Silva being referenced

Abstract 5358: The hypoxia-activated EGFR-TKI TH-4000 overcomes erlotinib-resistance in preclinical NSCLC models at plasma levels achieved in a Phase 1 clinical trial
2015
Abstract A66: Preclinical rationale for the ongoing Phase 2 study of the hypoxia-activated EGFR-TKI tarloxotinib bromide (TH-4000) in patients with advanced squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS)
2015
and 3 more

Author Peers

Author Last Decade Papers Cites
Shevan Silva 73 154 68 144 136 17 350
Bertrand Heckmann 43 57 42 229 98 16 392
Antonio Serafín 66 85 17 166 108 34 337
Daniel P. Camarco 50 51 28 155 123 21 404
Andrea L. Merz 62 41 51 193 114 14 376
Nicole Willemsen‐Seegers 46 47 61 226 97 18 358
Lori Rice 73 59 23 152 72 20 366
Kazuhisa Minamiguchi 71 53 56 142 38 25 394
E Tweedle 37 106 43 169 204 11 387
Brigitte Simon 113 51 22 193 104 19 411
Megumi Morimoto 63 82 26 172 46 18 356

All Works

Loading papers...

Rankless by CCL
2026